Atara Biotherapeutics, Inc
Veridion Score
Composite trend over time
Why is ATRA moving today?
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA3431, and ATA3219.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for ATRA.
ATRA insider activity
Atara Biotherapeutics, Inc
No multi-insider buying cluster in the last 90 days
Net buying: $3.8M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-05-20 | 2026-05-18 | Nguyen AnhCo | Insider | sell | $9.13 | 5,241 | 137,837 | $48K | SEC Form 4 |
| 2026-05-20 | 2026-05-18 | Grant-Huerta Yanina | Insider | sell | $9.13 | 2,414 | 49,636 | $22K | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | EcoR1 Capital, LLC | Insider | buy | $9.35 | 507,407 | 1,552,000 | $4.7M | SEC Form 4 |
| 2026-05-11 | 2026-05-07 | Huang James | Insider | sell | $10.10 | 313,446 | 1,011,000 | $3.2M | SEC Form 4 |
| 2026-03-19 | 2026-03-17 | Huang James | Insider | buy | $6.61 | 259,163 | Not reported | $1.7M | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 27 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moATRA contract awards, year to date.
Public federal awards linked to this ticker.
ATRA lobbying filings, year to date.
Registered lobbying filings matched to Atara Biotherapeutics, Inc.